Table 2.
Characteristics of the patients treated with nivolumab.
| Total | Thyroid dysfunction | p value | ||
|---|---|---|---|---|
| (−) | (+) | |||
| (n = 147) | (n = 132) | (n = 15) | ||
| Tumour type | ||||
| MM | 24 | 22 | 2 | 0.103 |
| NSCLC | 54 | 50 | 4 | |
| RCC | 21 | 18 | 3 | |
| HN | 28 | 24 | 4 | |
| GC | 19 | 17 | 2 | |
| HL | 1 | 0 | 1 | |
| Sex | ||||
| Male | 104 | 94 | 10 | 0.767 |
| Female | 43 | 38 | 5 | |
| Age, years (range) | 64 ± 12 | 64 ± 12 | 63 ± 11 | 1.000 |
| (28–86) | (28–86) | (40–78) | ||
| Follow-up period (days) | 346 ± 261 | 340 ± 262 | 392 ± 255 | 0.473 |
| History of prior immunotherapy | 10 | 9 | 1 | 1.000 |
| Positive for anti-thyroid antibodies at baseline | 26 | 15 | 11 | < 0.001 |
MM malignant melanoma, NSCLC non-small-cell lung carcinoma, RCC renal cell carcinoma, HN head and neck cancer, GC gastric cancer, HL Hodgkin lymphoma.